Sağlık Sitelerinden Haberler


        
 
Bilgi:
Etiketler:
Yazarın adı:
Yazarın soyadı:


EklenmeTarihi: 21 Mayıs 2022, Cumartesi, 00:06
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021
In May 2021, after a systematic review of all available data, the Advisory Committee on Immunization Practices made an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years for the prevention of COVID-19.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=422060
Etiketler:

EklenmeTarihi: 21 Mayıs 2022, Cumartesi, 00:06
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Excess Death Estimates in Patients with End-Stage Renal Disease - United States, February-August 2020
Based on the national trend in ESRD deaths during the first 7 months of the U.S. COVID-19 pandemic (February-August 2020), an estimated 8.7-12.9 excess deaths per 1,000 patients or 6,953-10,316 excess deaths in a population of 798,611 U.S. ESRD patients occurred.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=423046
Etiketler:

EklenmeTarihi: 21 Mayıs 2022, Cumartesi, 00:06
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021
As of April 30, 2021, approximately 101 million people in the U.S. had been fully vaccinated against COVID-19. Almost 10,300 COVID-19 vaccine breakthrough infections were reported from 46 states and territories. Vaccine breakthrough infections occur in only a small fraction of all vaccinated people.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=422857
Etiketler:

EklenmeTarihi: 21 Mayıs 2022, Cumartesi, 00:06
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021
The first U.S. multisite test-negative design vaccine effectiveness study among HCP found a single dose of Pfizer-BioNTech or Moderna COVID-19 vaccines to be 82% effective against symptomatic COVID-19 and 2 doses to be 94% effective.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=422061
Etiketler:

EklenmeTarihi: 21 Mayıs 2022, Cumartesi, 00:06
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Identification of and Surveillance for the SARS-CoV-2 Variants B.1.427 and B.1.429 - Colorado, January-March 2021
On January 24, the Colorado Department of Public Health and Environment (CDPHE) identified the first Colorado case of COVID-19 attributed to the B.1.427 and B.1.429 variants. To improve convenience sampling to identify and track emerging variants, CDPHE established a 30-site statewide sentinel surveillance system.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421658
Etiketler:

EklenmeTarihi: 21 Mayıs 2022, Cumartesi, 00:06
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021
Five mass vaccination sites reported 64 anxiety-related events, including 17 events of syncope (fainting) after receipt of Janssen COVID-19 vaccine. The reporting rates of syncope to VAERS after Janssen COVID-19 and influenza vaccines (2019-20) were 8.2 and 0.05 per 100,000 doses, respectively.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421542
Etiketler:

EklenmeTarihi: 21 Mayıs 2022, Cumartesi, 00:06
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021
In U.S. hospitals during January-March 2021, receipt of Pfizer-BioNTech or Moderna COVID-19 vaccines was 94% effective against COVID-19 hospitalization among fully vaccinated adults and 64% effective among partially vaccinated adults aged ≥65 years.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421438
Etiketler:

EklenmeTarihi: 21 Mayıs 2022, Cumartesi, 00:06
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Linked Clusters of SARS-CoV-2 Variant B.1.351 - Maryland, January-February 2021
This report describes an investigation in Maryland of two linked clusters of COVID-19 cases identified as the B.1.351 variant.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421458
Etiketler:

EklenmeTarihi: 21 Mayıs 2022, Cumartesi, 00:06
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021
Nearly 8 million doses of the Janssen COVID-19 vaccine had been administered. Review of safety monitoring data found that 97% of reported reactions after vaccine receipt were nonserious, consistent with preauthorization clinical trials data. A total of 17 thrombotic events with thrombocytopenia were detected, including three non-CVST events.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421539
Etiketler:

EklenmeTarihi: 21 Mayıs 2022, Cumartesi, 00:06
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021
The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA's Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18-49 years.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421416
Etiketler: